There is a quote often attributed to Einstein: compound interest is the eighth wonder of the world. He who understands it, ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) found that certain lifestyle interventions improved cognition in older ...

The federal government is looking for researchers who can, in 5 years, develop stem cell treatments to repair brain damage caused by stroke, neurodegeneration, and trauma. The Functional Repair of ...

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the Department of Health and Human Services, on Thursday unveiled the Functional Repair of Neocortical Tissue (FRONT) ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...

In a series of stories, AL.com will continue to explore big ideas for transforming Birmingham - ideas, programs and initiatives aimed at making the city stronger, more prosperous, better educated and ...